Product Description
Mechanisms of Action: IGF Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Breast Cancer
Phase 1: Oncology Solid Tumor Unspecified|Oncology Unspecified|Hepatocellular Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2011-000198-29 | P2 |
Completed |
Breast Cancer |
2019-06-28 |
|
CD-ON-MEDI-573-1030 | P2 |
Completed |
Breast Cancer |
2019-06-28 |
|
MEDI-573-1028 | P1 |
Completed |
Hepatocellular Carcinoma |
2013-04-09 |
|
MI-CP184 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2012-09-11 |